Shares of several biotech companies developing obesity drugs increased sharply on Monday after Pfizer halted development of its experimental pill, sparking hopes for mergers and acquisitions. Viking Therapeutics Inc. jumped nearly 11%, Structure Therapeutics Inc. climbed around 19%, Terns Pharmaceuticals Inc. rose 7.9%, while Metsera Inc. surged around 30%.
Source: https://www.bloomberg.com/news/articles/2025-04-14/pfizer-setback-spurs-rise-in-obesity-developers-on-m-a-hopes